NEW BRUNSWICK, N.J. / Apr 28, 2025 / Business Wire / Johnson & Johnson (NYSE: JNJ) will present at the Bernstein’s 41st Annual Strategic Decisions Conference on Wednesday, May 28th, 2025. Management will participate in a Fireside Chat at 10:00 a.m. Eastern Time.
A live audio webcast of the presentation will be accessible through Johnson & Johnson’s Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day.
The audio webcast replay will be available approximately 48 hours after the webcast.
| Last Trade: | US$188.64 |
| Daily Change: | 2.66 1.43 |
| Daily Volume: | 8,425,344 |
| Market Cap: | US$454.620B |
September 15, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
